{
    "Trade/Device Name(s)": [
        "GAL-IC Blood Glucose Monitoring System",
        "GAL-1C Blood Glucose Test Strips",
        "Contrex Plus III Glucose Control Solution",
        "Contrex Plus II Glucose Control Solutions"
    ],
    "Submitter Information": "Apex BioTechnology Corp.",
    "510(k) Number": "K102816",
    "Predicate Device Reference 510(k) Number(s)": [
        "K073648",
        "100747"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "CGA",
        "NBW",
        "JJX"
    ],
    "Summary Letter Date": "August 22, 2011",
    "Summary Letter Received Date": "August 23, 2011",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 862.1345",
        "21 CFR 862.1660"
    ],
    "Regulation Name(s)": [
        "Glucose Test System",
        "Single (specified) analyte controls (assayed and unassayed)"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "tdm"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Capillary whole blood"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "GAL-IC Blood Glucose Meter"
    ],
    "Method(s)/Technology(ies)": [
        "Electrochemical detection"
    ],
    "Methodologies": [],
    "Submission Type(s)": [
        "System",
        "Test Strips",
        "Control Solution",
        "Meter"
    ],
    "Document Summary": "FDA 510(k) summary for GAL-IC Blood Glucose Monitoring System, test strips, and control solution for quantitative measurement of blood glucose in capillary whole blood.",
    "Indications for Use Summary": "Intended for quantitative measurement of glucose in fresh capillary whole blood from fingertips, forearm, or palm for monitoring Diabetes Mellitus; not for diagnosis or neonatal use; control solution for validating performance of the monitoring system.",
    "fda_folder": "Clinical Chemistry"
}